ESC 365 - Should we abandon EF to stratify heart failure treatment?

ESC Premium Access

Should we abandon EF to stratify heart failure treatment?

Session: Heart failure with mid-range and preserved ejection fraction

Topic: Miscellaneous

Speaker: Professor S. Solomon (Boston, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

73 presentations

28 followers

4 more presentations in this session

State of the Art: HFmrEF - The new middle child

Speaker: Professor R. De Boer (Rotterdam, NL)

Patterns and prognostic role of N-terminal pro-B-type Natriuretic Peptide in heart failure with mid-range vs. preserved vs. reduced ejection fraction

Speaker: Doctor G. Savarese (Stockholm, SE)

Prognostic relevance of the 40% left ventricular ejection fraction cut-off in chronic systolic heart failure

Speaker: Doctor A. Aimo (Pisa, IT)

Prognostic relevance of preclinical diastolic dysfunction across left ventricular ejection fraction categories. The DAVID-Berg study

Speaker: Doctor M. Gori (Bergamo, IT)

Access the full session

Heart failure with mid-range and preserved ejection fraction

Speakers: Professor S. Solomon, Professor R. De Boer, Doctor G. Savarese, Doctor A. Aimo, Doctor M. Gori

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources